Aim To describe the inappropriate use of traditional nonsteroidal anti-inflammatory drugs (tNSAIDs) in elderly subjects in the CADEUS cohort using the Beers 2003 criteria modified by recommendations from the French Medicines Agency. Methods Of the 23,217 subjects in the CADEUS cohort, 1,851 were ≥65 years old, had bee diagnosed with osteoarthritis (OA), and had been dispensed a tNSAID at least once in the 6 months before the index date. Data were obtained from the French national reimbursement database and from patient and prescriber questionnaires. The Beers criteria for inappropriate use were modified to include all tNSAIDs, and long-term high-dose use was defined as having been dispensed at least five dispensations for tNSAID over a 6-month period with a gap of <45 days between each dispensation and when the gap was >45 days, medicine availability >50% [i.e., defined daily dose (DDD) delivered/ theoretical DDD] for the gap. Results The most frequently dispensed tNSAIDs were piroxicam (25%), diclofenac (24%), ibuprofen (18%), ketoprofen (18%), and naproxen (10%). Of the study population, 1.5% were dispensed indomethacin; 15%, two tNSAIDs; 15%, a tNSAIDs with a platelet aggregation inhibitor; 4.6%, a tNSAID with low-dose aspirin; 0.2%, a tNSAID with vitamin K antagonists. The analysis revealed that 18% of the study population were high-dose and long-term users of tNSAIDs and that 70% of these were dispensed a proton pump inhibitor. Conclusions The most common inappropriate tNSAID dispensation was the co-prescription of two different tNSAIDs within 1 month or of a platelet aggregation inhibitor. The reallife consequences of our results need to be ascertained, and it would be interesting to update the Beers criteria.
Introduction
Non-steroidal anti-inflammatory drugs (NSAIDs) are among the most commonly used drugs for the relief of pain and inflammation in three main therapeutic areas: inflammatory rheumatisms [rheumatoid arthritis (RA), ankylosing spondylarthritis, or psoriasis arthritis], osteoarthritis (OA), and common painful disorders, such as headache, minor trauma or tendinitis, and dysmenorrhoea. The patterns of traditional non-selective (t) NSAID use are quite different between the three main indication domains, with essentially continuous use in rheumatic diseases, intermittent chronic use [100+ defined daily dose (DDD) per year] in OA, and a few days at usually lower doses in common pain. The age groups concerned are also quite different, with OA patients usually being older, with a mean age of 66 years, compared to 55 years for RA and 43 years for common pain. Two-thirds of elderly patients (≥65 years of age) taking tNSAIDs do so for OA (approximately 35%) or back pain (approximately 32%) [1] [2] [3] .
NSAIDs inhibit cyclooxygenase (COX) enzymes, resulting in an inhibition of the synthesis of prostaglandins [4] . This in turn increases the susceptibility of the stomach mucosa to acid aggression, but also may result in renal dysfunction with an in increased plasma volume. More recently, following the marketing of the COX-2-specific inhibitors [5, 6] , an increased risk of myocardial infarction has been suggested for all NSAIDs [7] .
Age above 65 years, previous gastrointestinal (GI) history (esophageal ulcer, gastro-duodenal ulcer, perforated ulcer, or upper gastrointestinal bleeding), prolonged NSAID use, and high doses of NSAIDs are among the well-known risk factors for GI bleeding. In addition, the risk is higher with certain drugs with long half-lives, such as piroxicam, or with those having a strong COX-1 inhibition, such as naproxen or indomethacin. GI bleeding in the elderly is a matter of concern because of the increased frailty of these patients, the presence of commonly concomitant vascular diseases, and the increased risk of acute renal failure related to bleeding-induced hypovolemia magnified by renal COX-2 inhibition. Renal failure as well as aggravated (or even induced) heart failure are also potential and serious side effects of NSAIDs. Accordingly, strong recommendations have been made to ensure the proper prescription of NSAIDs in patients who need them, and these are embodied in the Beers criteria (modified in 2002) [8] [9] [10] , in regulatory recommendations [11, 12] , and in the indications for gastroprotection with proton pump inhibitors (PPIs) in certain countries.
The updated 2003 Beers criteria define inappropriate medication use in older adults either independently or considering the diagnosis or conditions [10] . According to the NSAIDs listed in Beers criteria and its rationale, all use of indomethacin and ketorolac should be avoided independent of diagnoses or conditions. Additionally, long-term use of high-dose tNSAIDs (naproxen, oxaprozin, piroxicam) should be avoided as they have a potential for inducing renal failure, GI bleeding, hypertension, and heart failure. Patients with gastric or duodenal ulcers should avoid using tNSAID (coxibs excluded) and aspirin >325 mg/day since these drugs may exacerbate existing ulcer disease or create new ulcers. Furthermore, patients with blood clotting disorders (including anticoagulant therapy) should not use aspirin, NSAIDs (tNSAIDs or coxibs), as well as dipyridamole, ticlopidine, and clopidogrel since there is an increased risk of bleeding through multiple mechanisms of action [10] .
The French Medicines Agency (Agence française de sécurité sanitaire des produits de santé, Afssaps) has published a recommendation for the rational prescribing of NSAIDs that takes the prescription of ketoprofen and piroxicam into account [11] . Ketorolac is no longer on the French Market. Afssaps recommends the use of NSAIDs with the minimum effective dose and for the shortest possible duration of time. Contraindications can be summarized as follows:
& NSAIDs (tNSAIDs or coxibs) should not be prescribed if the patient has a history of peptic ulcer disease, NSAID-induced GI bleeding, or severe heart failure. & To avoid drug-drug interactions, NSAIDs (tNSAID, coxibs or, aspirin at anti-inflammatory doses ≥325 mg/day) should not be co-prescribed.
It is also recommended to take into account that coprescription of NSAIDs with platelet aggregation inhibitors increases the risk of GI bleeding.
In order to study the use of COX-2-selective NSAIDs celecoxib and rofecoxib compared to that of tNSAIDs, the French regulatory authorities commissioned a large-scale study, CADEUS (COX-2 inhibitors and NSAIDs: description of users), whereby patients were identified by the dispensation of a coxib or tNSAID; further information was obtained from the prescriber of the patient. Dispensation of other drugs and use of healthcare resources during the 6 months before and after the index selection date were obtained from the national reimbursement database. This cohort has already been described [2] , as has the determinants of coxib use, with the results showing that these were used almost exclusively in patients with RA. The main drivers of coxib prescription were age, female gender, previous gastrointestinal history, and previous use of PPIs [3] .
In the CADEUS cohort, the main indication for NSAID prescription among the patients aged >65 years was OA. Here, we report the results of our study of the elderly patients using tNSAIDs for OA in the CADEUS study to test adherence to Beer's criteria and to the recommendations of Afssaps.
Materials and methods
Data sources: CADEUS study description CADEUS is a national prospective cohort study of the characteristics of a random sample of patients registered in the database of the French National Healthcare Insurance System for salaried persons (CNAM-TS), which covers 80% of the French population, and who submitted a claim for celecoxib, rofecoxib, or tNSAIDs during the study period (1 August 2003 to31 July 2004). Patients were assigned an index date equivalent to the date of celecoxib, rofecoxib, or tNSAID dispensation. Study methods have been described in detail elsewhere [2] . In brief, there were three parallel cohorts based on the product of the index dispensation aiming to recruit 10,000 patients with a celecoxib dispensation, 10,000 patients with a rofecoxib dispensation, and 20,000 patients with a tNSAID dispensation. All NSAIDs with the M01A code in the World Health Organization Anatomical Therapeutic Chemical (ATC) classification were considered. Glucosamine was excluded, although it does belong to the M01A group, owing to its different pharmacological properties. Aspirin in combination with corticosteroids (ATC code M01BA03) was not included in the analysis as it is not marketed in France. Low-dose NSAIDs (at analgesic doses) used only for analgesia or antipyrexia as well as all forms of aspirin were excluded from the selection process, but not from the data collected. Only orally administered NSAIDs were included. The medical history of each patient was based on physician-declared data; previous gastrointestinal history was defined as dyspepsia, gastro-esophageal reflux disease (GERD), esophageal ulcer, gastro-duodenal ulcer, perforated ulcer, or upper gastrointestinal bleeding; previous cardiovascular history was defined as arterial hypertension, myocardial infarction, unstable angina, angina pectoris, left ventricular insufficiency, lower limb arthritis, ischemic or hemorrhagic stroke, diabetes mellitus, or hypercholesterolemia.
Study design and study population
The population of this study is a part of the CADEUS study and consisted of patients aged ≥65 years with diagnosed OA who had filed a reimbursement claim for a tNSAID (index drug, ATC code: M01A) during the study period (1 August to 31 July 2004) and for at least one tNSAID (index or other tNSAID) in the preceding 6 months (n=1,851). Such patients were considered to have been exposed to a tNSAID.
Data analysis
According to the modified Beers list and the Afssaps recommendations, inappropriate tNSAID use is (1) the dispensation of indomethacin, (2) at least one dispensation of two different tNSAIDs within 1 month, and (3) at least one dispensation of tNSAIDs either with platelet aggregation inhibitors (ATC code B01AC), vitamin K antagonists (VKAs) (ATC code B01AA), or aspirin ≥325 mg/day (ATC code M01BA03) within 1 month. To better characterize inappropriate users of tNSAIDs, we also took into account all drug use in the previous 6 months [acid-suppressing agents (PPIs, ATC code A02BC), cardiovascular agents]. In France, prescribed NSAIDs are delivered in non-divisible packets containing, for the most part, 30 delivery units. Therefore, long-term use of high-dose (anti-inflammatory) tNSAIDs was defined as having at least five tNSAID dispensations over a 6-month period with a gap of <45 days between each of these, or when the gap was >45 days, medicine availability >50% (i.e., DDD delivered/theoretical DDD for the gap). The DDDs of the tNSAIDs were those listed in the ATC/DDD index 2007.
Statistical analyses were descriptive and performed using the SAS statistical program ver. 9.1 (SAS Institute, Cary, NC).
Regulatory aspects
The protocol was submitted to and validated by the French National Data-protection Commission in charge of authorizing data-processing (CNIL: Commission Nationale de l'Informatique et des Libertés) and the French National Council of Physicians (CNOM: Conseil National de l'Ordre des Médecins). All participating subjects gave written informed consent. For purely observational studies performed in France, approval from an ethics committee is not required, and the CADEUS study was therefore not submitted for approval.
Results
Within the CADEUS tNSAID cohort, 1,851 OA patients were identified according to the inclusion criteria and constituted our study population (28.4% male; Table 1 ). In the study population, the five most frequently reimbursed tNSAIDs over the study period were piroxicam (25.0%), diclofenac (24.0%), ibuprofen (18.0%), ketoprofen (18.0%), and naproxen (10.0%). The maximum number of dispensations over the 1-year study period was 7 (n=2), and 22.6% of the study population were long-term users of tNSAIDs. The overall prevalence of patients with at least one criterion defining inappropriate use NSAID was 43.0%. Each criterion was then considered separately. Indomethacin had been dispensed to 1.5% (n=28) of the study population, with 11 patients being dispensed indomethacin only once. Within a 1-month period, 279 (15.0%) patients had received two different tNSAIDs, of whom 85 (4.6%) were dispensed aspirin and a tNSAID, and 275 (15.0%) were dispensed a platelet aggregation inhibitor and a tNSAID. Across these groups, age ranged from 73.2 to 76.2 years, the presence of previous cardiovascular history ranged from 60.9 to 85.8% and that of a previous gastrointestinal history from 29.0 to 39.3%. Among those who were dispensed indomethacin, 39.3% did not use gastroprotective agents in the previous 6 months; this lack of a prescription for gastroprotective agents also held for 41.2% of those dispensed two different tNSAIDs within 1 month, 54.1% of those dispensed aspirin and tNSAIDs within 1 month, and 52.0% of those dispensed a platelet aggregation inhibitor and tNSAIDs within 1 month (Table 2) .
Among those dispensed two different tNSAIDs at least once within 1 month (n=279) the most frequent combinations were ketoprofen with piroxicam (11.0%), diclofenac with piroxicam (10.0%), diclofenac with ibuprofen (8.0%), and diclofenac with ketoprofen (7.5%) ( Table 3) . Among those dispensed tNSAIDs with a platelet aggregation inhibitor within 1 month (n=275), the most frequent tNSAIDs were diclofenac (27.0%), piroxicam (23.0%), ibuprofen (19.0%), and ketoprofen (15.0%) ( Table 4) . Of the four patients dispensed tNSAIDs with VKAs, the tNSAIDs were diclofenac (0.05%), indomethacin (0.05%), ketoprofen (0.10%), and piroxicam (0.05%). Among those dispensed tNSAIDs with low-dose aspirin, the most frequent tNSAIDs were piroxicam (31%), diclofenac (22%) or ibuprofen (19%) ( Table 5 ).
Discussion
Our results indicate a variable but often inappropriate prescription of tNSAIDs in a population of elderly OA patients according to the criteria considered. Beers criteria recommend that the use of either indomethacin or ketorolac is inappropriate in the elderly. Only 1.5% of our study population were prescribed indomethacin, and none was prescribed ketorolac, which is no longer on the French market. Only four subjects were co-dispensed a tNSAID with a VKA. On the other hand, 4.6% of the elderly patients concomitantly used low-dose aspirin, and 15% were prescribed two different tNSAIDs at least once within 1 month or were co-prescribed antiplatelet agents.
Since October 2005, two NSAIDs have been the focus of particular attention in Europe and France: ketoprofen and piroxicam [12] . For piroxicam, an arbitrage procedure was triggered due to its serious digestive and cutaneous side effects. For ketoprofen, although the risk/benefit ratio is positive, the daily dosage should not exceed 200 mg. In our study cohort, 25 and 20% of the study population were prescribed piroxicam and ketoprofen at least once, respectively. Traditional NSAIDs should be used at the minimum effective dose and for the shortest possible duration [11] . Since the 2003 Beers criteria did not define high dose and long-term NSAIDs utilization, this was defined in the current investigation. All tNSAIDs were included in the analysis of high-dose and long-term use even though Beers criteria specifically finger naproxen, oxaprozin, piroxicam, whereas AFSAPPSS does not specify whether any drugs present a specific risk. Although OA is a chronic painful disease, only 22.6% of our study population were users of high-dose tNSAIDs on a long-term basis, which is consistent with known patterns of use of NSAIDs in France [1, 13, 14] .
The prescription of two or more NSAIDs is not recommended, especially in the elderly due to the increased risk of adverse side effects. In our study population, the prevalence of dispensation of two NSAIDs was 15%. However, as dispensed drugs may not actually be taken by the patient, this figure may not necessarily reflect the true prevalence of concomitant intake. It may also indicate prescriber modulation in which prescription is used according to symptoms (i.e., riskier drugs, such as piroxicam, kept for longer periods of time to treat flares or exacerbations of the disease and shorter-acting NSAIDs, such as ibuprofen, ketoprofen, or diclofenac, for less severe episodes). The main problem of multiple NSAID use is their increased risk of GI toxicity related to the overall NSAID burden. In these cases, the use of gastroprotective agents might alleviate the risk; it was therefore interesting to note the lower rate of non-users of gastroprotective agents among this population and in patients prescribed indomethacin (Table 2) .
Many studies have established the increased gastrointestinal toxicity of tNSAIDs and, therefore, the use of gastroprotective agents for patients with risk factors for gastrointestinal complications, such as age >65 years, history of a peptic ulcer, and concomitant use of anticoagulants drugs or acetylsalicylic acid, is highly recommended [15] . In our study population, the prevalence of gastroprotective agent users among chronic NSAIDs users (chronic and continuous) ranged between 36 and 60% for each criterion.
One of the limitations of our could be that only patients registered in the French general healthcare insurance Data are shown as the number of dispensations, with the percentage in parenthesis. Percentage = percentage of total dispensations (n=85) of tNSAIDs in combination with low dose aspirin system were included in the whole CADEUS cohort; however, this system does cover 85% of the French population. Beers criteria have become the most widely cited criteria for inappropriate prescribing in the elderly; nevertheless, some deficiencies are known [16, 17] . As the last version of these was published in 2003, they need updating, in particular, with respect to the use of nonselective NSAIDs versus COX-2 selective NSAIDs and the concomitant use of gastroprotective drugs, which alleviate some of the risks related to NSAIDs in the elderly, although other risks are not modified (e.g., renal failure or cardiovascular events). Such updating necessitates careful assessment to avoid depriving those patients who need NSAIDs of their medication.
The elderly are at significant risk for increased adverse drug reactions for several reasons. As such, physicians should be extra cautious in prescribing tNSAIDs to elderly patients, especially those who have risk factors. Appropriate conduct would include avoiding these drugs when possible (while acknowledging that substitutes, such as paracetamol or opiates, are also not wholly devoid of problems) or using measures to counter the risk, such as gastroprotective agents, and careful monitoring of the patients and their therapeutic options.
Conclusion
The most common inappropriate dispensions of NSAIDs were the co-prescription of different NSAIDs within 1 month and the co-prescription of a NSAID with platelet aggregation inhibitor. The real-life consequences of these prescriptions need to be ascertained.
